The GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTNEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →Same-day shipping now live from the US West Coast · order by 2:30 PM PT weekdays, 12:00 PM PT Saturday →NEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →
Disguised Alpha Β· CBL-514 Research

CBL-514’s 2025 Placebo-Controlled Study Explained

Quick answer

The 2025 CBL-514 study compared the investigational formulation with placebo using ultrasound-based abdominal fat measurements. Its headline responder percentage describes a defined threshold at a defined visit, not a percentage of total body fat lost.

Disguised Alpha Β· November 11, 2026 Β· Sources reviewed November 11, 2026

Read the endpoint before the percentage

Gold and colleagues randomized 76 participants in a single-blind Phase II study. The primary endpoint concerned the proportion reaching at least 150 mL of subcutaneous fat-volume reduction. At eight weeks after final treatment, the reported responder proportions were 69.6% with CBL-514 and 0% with placebo.[1]

β€œ69.6% responded” does not mean β€œ69.6% fat reduction.” The first is a fraction of people meeting a rule; the second would describe the size of a tissue change. Retaining the endpoint wording prevents a substantial misinterpretation.

A practical reading sequence

  1. Write down the response threshold and anatomical region.
  2. Identify which follow-up visit the number belongs to.
  3. Find the population used in that analysis.
  4. Check the number with data at that visit.
  5. Read the comparison and uncertainty alongside the point estimate.

The total randomized population is not necessarily the denominator behind every reported percentage. A table can use available observations at one visit, a specified analysis set or a model. Locate the paper’s explanation before reconstructing a number yourself.

ClinicalTrials.gov’s results guide separates participant flow, baseline characteristics, outcomes and adverse events. That is a useful order for reviewing a published paper as well.[2]

What to carry into a literature summary

Keep the study-specific measurement and comparator in the same sentence as the result. Avoid replacing a threshold with a vague β€œsuccess rate,” which hides the definition of success. Also distinguish group-level findings from predictions about an individual outcome.

For an internal evidence table, create separate columns for randomized participants, evaluable participants, response threshold and follow-up. Leave a blank when a figure has not been checked rather than filling it with a number from another table.

These results concern the investigational formulation used in the study. They are not a certificate for a DA lot, and they do not establish an approved use for a separately supplied material.

Frequently asked questions

Is the responder percentage the same as percent fat loss?

No. It describes the share of participants meeting the specified threshold.

Can the overall enrollment be used for every calculation?

Only if the source defines it as the denominator for that calculation. Check the analysis set and visit-specific data.

CBL-514 product and documentation

Review the current format and pack choices, then match the supplied lot to its documentation. No batch-specific identity, purity or content result is asserted in this article.

Sources

  1. Gold et al., 2025 Phase II study; doi:10.1093/asj/sjaf032
  2. ClinicalTrials.gov: reading study results

Publisher disclosure: Disguised Alpha sells the research material linked here. This supplier-published article provides research education and editorial interpretation; it is not an independent clinical review. Literature findings do not establish the identity or clinical performance of DA material.

Laboratory research only. Not for human or veterinary use. No affiliation with Caliway is claimed.

βœ“
Loading...
25% offGLPs15% off automaticallyUse code GLP or any code for 25% off0days00hrs00min00secShop the sale  →Shop